1 Treatment advantage in HBV/HIV coinfection compared to 2 **HBV** monoinfection in a South African cohort 3 4 Tongai G Maponga<sup>1</sup>, Anna L McNaughton<sup>2</sup>, Marije Van Schalkwyk<sup>3</sup>, Susan Hugo<sup>3</sup>, 5 Chikezie Nwankwo<sup>4</sup>, Jantiie Taliaard<sup>3</sup>, Jolynne Mokaya<sup>2</sup>, David A Smith<sup>2</sup>, 6 Cloete van Vuuren<sup>5</sup>, Dominique Goedhals<sup>6</sup>, Shiraaz Gabriel<sup>4</sup>, Monique I Andersson<sup>1,7</sup>, 7 Wolfgang Preiser<sup>1</sup>, Christo van Rensburg<sup>4</sup>, Philippa C Matthews<sup>2,7,8</sup> 8 9 <sup>1</sup> Division of Medical Virology, Stellenbosch University / National Health Laboratory Service 10 11 Tygerberg, Cape Town, South Africa 12 <sup>2</sup> Nuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, 13 Oxford, UK <sup>3</sup> Division of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg 14 Academic Hospital, Cape Town, South Africa 15 16 <sup>4</sup> Division of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa 17 18 <sup>5</sup> Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, 19 University of the Free State, Bloemfontein, South Africa 20 <sup>6</sup> Division of Virology, Universitas Academic Laboratories, National Health Laboratory 21 Service/University of the Free State, Bloemfontein, South Africa <sup>7</sup> Department of Microbiology and Infectious Diseases, Oxford University Hospitals, John 22 23 Radcliffe Hospital, Headington, Oxford, UK 24 8 NIHR British Research Council, John Radcliffe Hospital, Headington, Oxford, UK 25 26 \* Corresponding author: philippa.matthews@ndm.ox.ac.uk 27 **Keywords:** hepatitis B virus, HBV, HIV, treatment, elimination, viral load, tenofovir, dolutegravir, 28 hepatocellular carcinoma, South Africa, coinfection, sustainable development goals 29 30 31 32 33

### **ABSTRACT**

34

35 36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Objective: Prompted by international targets for elimination of hepatitis B virus (HBV) infection, we performed a cross-sectional observational study of adults with chronic HBV (CHB) infection in South Africa, characterising individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in clinical care as guidelines for antiviral therapy change over time. Design: We prospectively recruited 112 adults with CHB, of whom 38 (34%) had HIV coinfection, over one year in a university hospital in Cape Town, South Africa. We recorded cross-sectional demographic, clinical and laboratory data. Results: Adults with HBV monoinfection were comparable to those with HBV/HIV coinfection in terms of age, sex and body mass. HBeAq-positive status was more common among those with coinfection (p=0.01). Compared to HBV/HIV coinfection, HBV monoinfected patients were less likely to be on antiviral treatment and less likely to have been assessed by fibroscan (p<0.0001 in each case); they were also more likely to have detectable HBV viraemia (p=0.01), moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.002), and APRI score >2 (p=0.02), suggesting underlying liver disease. Three cases of hepatocellular carcinoma were reported, all in patients with HBV monoinfection. Conclusion: Individuals with HBV monoinfection are disadvantaged in terms of clinical assessment and appropriate antiviral therapy compared to those with HIV coinfection, associated with relatively worse liver health. Enhanced advocacy, education, resources and infrastructure are required to optimise interventions for CHB.

### **'SUMMARY BOX'**

## What is already known about this subject?

Chronic infection with hepatitis B virus (HBV) is the cause of a substantial burden of disease in sub-Saharan Africa, with morbidity comparable to that caused by tuberculosis or malaria. Rates of liver disease associated with HBV are rising, but international sustainable development goals have set ambitious targets for elimination of the infection as a public health threat by the year 2030. In many parts of southern Africa, HBV is co-endemic with HIV infection. The conventional paradigm has been that the coinfection is associated with worse outcomes from both infections. However, this accelerated pathology may be halted by the introduction of antiviral therapy, with tenofovir being central to regimens for both HIV and HBV infection. This agent suppresses viral replication, leading to improved outcomes in both HIV and HBV infection, but certain questions remain to be considered, including its role in coinfection, the risk of drug resistance and toxicity, and the impact of changing antiretroviral regimens over time.

# What are the new findings?

We have studied adults with CHB under review at a teaching hospital in South Africa, reviewing clinical and laboratory data in the presence and absence of HIV coinfection. The group with coinfection was statistically more likely to be HBeAg-positive, suggesting an increased risk of accelerated liver disease. However, we show that the HBV monoinfected group are in fact disadvantaged: they are less likely to be on antiviral therapy (even when meeting treatment criteria), and therefore less likely to be virologically suppressed. Furthermore, coinfected patients are less likely to undergo full clinical evaluation and are characterised by increased rates of liver disease based on a range of markers including platelet count, bilirubin and fibrosis scores. We found no evidence of nephrotoxicity in association with the use of tenofovir. Thus, overall we show that the HBV monoinfected group have worse liver outcomes in comparison to those with HBV/HIV coinfection. Those with HIV coinfection have a therapeutic advantage, as a result of secure access to monitoring and consistent provision of antiviral therapy, and there is no evidence of a risk of toxicity associated with treatment.

# How might it impact on clinical practice in the foreseeable future?

Those with HBV monoinfection are vulnerable to evolving complications. We highlight the importance of careful clinical surveillance of this group, the importance of early diagnosis and

investigation, and a low threshold for the introduction of antiviral therapy. As antiretroviral therapy regimens change over time, with a move towards dolutegravir-based dual therapy, there is a risk of HBV/HIV-infected patients losing access to tenofovir therapy. Our results highlight the importance of maintaining tenofovir provision and scaling up treatment at a population level in order to make progress towards 2030 elimination targets.

### INTRODUCTION

The burden of chronic infection with hepatitis B virus (HBV) in southern Africa is high, and in this setting the distribution overlaps with populations in which HIV infection is endemic [1]. Due to high rates of coinfection, and the overlap in antiviral regimens, there is a pressing need to develop an enhanced understanding of the interplay between these infections, and to capitalise on opportunities for deploying existing HIV infrastructure to improve HBV diagnosis, clinical care and prevention. International sustainable development goals set a target for elimination of HBV as a public health problem by the year 2030 [2]. Developing insights into the characteristics and outcomes of chronic HBV (CHB) monoinfection and HBV/HIV coinfection will underpin improved strategies for monitoring, prognostication, patient stratification and therapy. Changes in recommendations for cART regimens for HIV infection should consider the individual and public health impact of therapy on individuals who are co-infected with HBV, particularly in the coendemic populations of sub-Saharan Africa.

A traditional paradigm suggests that individuals with HBV/HIV coinfection might have a worse prognosis from chronic liver disease than those with HBV monoinfection, typically linked with higher rates of HBeAg-positivity and higher viral loads [1,3], lower CD4+ T cell counts, increased incidence of liver fibrosis [4] and hepatocellular carcinoma (HCC), higher rates of vertical HBV transmission, and higher overall mortality [5]. However, this picture is not consistent between populations (even within individual studies [6]) and the interplay between viruses may be affected by specific characteristics of the host or viral population [7], and by changes in treatment guidelines over time.

Lamivudine (3TC) and tenofovir (most commonly in the form of tenofovir disoproxil fumarate, TDF) have established track records of safety and tolerability in both HIV and HBV infection. Long-term 3TC use is hampered by a high rate of selection of resistance [8], while TDF is favoured as the genetic barrier to resistance is high [9]. Following publication of the START trial in 2015, HIV treatment is now initiated irrespective of clinical or immunological status [10]. This practice is now enshrined in '90-90-90' targets, seeking to have 90% of cases diagnosed, 90% of these on treatment, and 90% of these virologically suppressed [11]. TDF is one of the recommended choices for the NRTI backbone of cART for HIV [12]; in South Africa, TDF is used for first-line cART in combination with 3TC/EFV or FTC/EFV [13]. In second-line regimens, TDF is commonly added to a protease inhibitor (PI) with a backbone of zidovudine (AZT)+3TC.

Thus the majority of HIV-positive individuals with HBV coinfection receive TDF as a component of routine first or second-line therapy.

In contrast, for HBV monoinfection, TDF is prescribed only for a subset of patients, based on algorithms that incorporate assessment of the patient (age and sex), virologic status (HBV DNA viral load) and the presence of underlying fibrotic or inflammatory liver disease (ALT, elastography score, ultrasound appearance, biopsy results) [14–16]. WHO targets for 2030 aim for 90% of HBV cases to be diagnosed, and for 80% of those eligible for treatment to be receiving it [17]. However, only a small minority of those living with CHB are currently aware of their status [18], patient stratification and monitoring using laboratory and radiological approaches is not accessible in many settings [18], and current assessment misses a high proportion of patients who should be treated [19].

Recognising the need for improved characterisation of HBV infection, both alone and in combination with HIV coinfection, we have undertaken a cross-sectional analysis of adults with CHB in an urban cohort in South Africa. We set out to explore the differences between individuals with monoinfection and coinfection, and to compare rates and outcomes of antiviral therapy, with the aim of informing current and future therapeutic guidelines.

## **METHODS**

### Clinical cohort

We recruited adults with CHB infection, with or without HIV coinfection, attending routine clinical follow-up in hepatology and infectious diseases outpatient clinics at Tygerberg Hospital, a tertiary referral hospital in Cape Town. HIV clinics within the referral area are encouraged to send all patients diagnosed with HIV-HBV coinfection to the Tygerberg clinic for counselling and baseline investigations including clinical assessment, laboratory tests and elastography.

Patients are followed at the clinic at intervals according to the baseline findings.

Cases were defined as being HBsAg-positive (typically over a period of >6 months of clinical follow up) and were recruited into a cross-sectional cohort (Oxford-South Africa Hepatitis Cohort, 'OxSA-Hep'), commencing July 2018. We here present the results of a planned interim analysis of data after 12 months of recruitment.

We recorded treatment with antiviral therapy at the time of recruitment to the study, routine clinical laboratory data (including serological markers of HBV infection, creatinine, liver function tests and platelet count), and documented elastography scores when the patient had been assessed by fibroscan. We recorded data in a LabKey database [20] using a unique pseudonymised patient ID number.

## Generation and analysis of laboratory data

- 171 Biochemical and serological data were generated on the Cobas 6000 series e601 module
- analyzer (Roche Diagnostics GmbH, Germany). Platelet counts were obtained using the Advia
- 173 2120i analyzer (Siemens Healthcare Diagnostics Inc, USA). HIV and HBV viral loads were
- 174 measured using Cobas Ampliprep/Tagman tests (Roche Molecular Diagnostics, the
- 175 Netherlands).

164

165

166

167

168

169170

176

184

192193

- 177 The upper limit of normal (ULN) for ALT was 19 iu/ml for females and 30 iu/ml for males [16,21],
- 178 ULN for AST = 40 iu/ml, ULN for BR = 17 mmol/L. We calculated liver fibrosis scores, AST to
- 179 Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) as follows:
- APRI = (AST / ULN AST) / (Platelet count x 100)
- FIB-4 = (Age in years x AST) / (Platelet count \* √AST)
- We used thresholds of FIB-4 >3.25 (97% specificity, and positive predictive value of 65% for
- advanced liver fibrosis [22]), and APRI >2 (91% specific for cirrhosis [23,24]).
- 185 We measured renal function based on estimated glomerular filtration rate (eGFR) as follows:
- 186 x (creatinine (μmol/L)/88.4)<sup>-1.154</sup> x (age in years)<sup>-0.203</sup> x (0.742 if female) x (1.210 if black) [25].
- Normal renal function is defined as eGFR ≥ 90 ml/min/1.73m<sup>2</sup>. We grouped together individuals
- with renal impairment, defined as chronic kidney disease (CKD) Stage II (eGFR 60-89 ml/min)
- or Stage III (eGFR 30-59 ml/min). We defined moderate/severe thrombocytopaenia as a platelet
- 191 count <75 x  $10^3/\mu$ l [26].

## Elastography

- 194 Elastography to quantify liver stiffness (an assessment of inflammation and/or fibrosis) is not
- undertaken consistently in this setting, but is performed in a subset of patients at the discretion
- of the clinical team using the Fibroscan 402 (Echosens, Paris, France). Elastography scores are

not reliable in individuals with a high body mass index or during pregnancy, and would not be undertaken in these circumstances. Due to the cross-sectional nature of the cohort, we recorded elastography scores at a single time point only.

## Treatment indications and outcomes

We have referred to HBV treatment recommendations published by the UK National Institute for Clinical Excellence (NICE) [21], the European Association for the Study of the Liver (EASL) [15], and South African national guidelines [16]. All concur in advising tenofovir or entecavir as first-line options, and recommend that stratification for therapy should be based on laboratory parameters, on the presence and extent of existing liver disease assessed by imaging and/or biopsy, and on consideration of other individual clinical and demographic factors.

Due to resource constraints, liver biopsy is rarely undertaken in this setting and we have primarily used laboratory parameters to assess treatment eligibility. South African guidelines suggest consideration of therapy for individuals who are HBeAg-positive with HBV DNA >20,000 IU/ml and ALT above ULN, or who are HBeAg-negative with HBV DNA >2,000 IU/ml and ALT above ULN, with the aim of achieving durable suppression of HBV DNA to low or undetectable levels and normalisation of ALT [16]. Individuals with HIV coinfection are routinely treated with first line combined antiretroviral therapy (cART) that includes HBV-active agents [13]. In practice in this setting, TDF is therefore first line therapy for CHB, both in the presence and absence of HIV infection.

## Statistical analysis

- We analysed data using GraphPad prism v 8.0.1. For continuous variables, we used Mann Whitney Test; for categorical variables we used Fisher's Exact Test. Linear regression was used to assess associations between two continuous variables. For multivariate analysis, we performed multivariate logistic regression using bayesglm function of the R package.
- **Ethics**
- 226 Ethics approval was provided by University of Oxford Tropical Research Ethics Committee (ref.
- OXTREC 01-18) and Stellenbosch University Human Research Ethics Committee (HREC ref.
- 228 N17/01/013). All participants provided written valid informed consent. A STROBE statement to
- support the quality of this observantional study is available (Suppl. Table 1)

### Patient and Public Involvement

Our teams run an active program of public engagement, with events taking place throughout the year in the UK and in South Africa. We have recently redesigned patient information sheets based on feedback from the clinics at recruitment sites, to improve clarity and accessibility of communication [27].

## **RESULTS**

## Representation of HBV monoinfection and HIV/HBV coinfection in an adult cohort

We recruited 112 adults with HBV infection (55% male), representing 74 adults with HBV monoinfection (66%) and 38 with HBV/HIV coinfection (34%) (Fig 1). The full metadata are available in Suppl. Table 2. Summary data for the cohort are presented in Table 1, showing a comparison of attributes of HBV monoinfection and HBV/HIV coinfection. Extended material are presented in Suppl. Table 3. Based on small numbers and borderline statistical significance at univariate level, we did not anticipate multivariate analysis to demonstrate many significant variables, but those that were significant are referenced in the footnotes to Tables 1 and 2.

The majority of participants were of South African origin (88%; Suppl. Fig 1). There was no significant difference in sex, age or body weight between the monoinfected and coinfected groups (p=0.24, 0.28, and 0.20 respectively; Table 1). HBeAg-positive status was significantly more common among individuals with HIV coinfection (34%) compared to HBV monoinfected individuals (12%); p=0.009; Fig 2A; Table 1.

## Antiviral therapy and virologic outcomes in HBV monoinfection vs HIV/HBV coinfection

Antiviral therapy and outcomes are shown in Fig 1 and Table 2. As anticipated, based on HIV treatment guidelines [13], a significantly greater proportion of the coinfected group was on antiviral therapy compared to the monoinfected group (97% vs. 49% respectively, p<0.0001; Fig 2B; also significant on multivariate analysis). Accordingly, HBV DNA was more likely to be suppressed below the limit of detection in coinfected than monoinfected patients (57% vs 33%, respectively; p=0.03; Fig 2C), and absolute values for HBV DNA viral load (VL) were also significantly lower in the coinfected group than the monoinfected (p=0.049; Suppl Fig 2A). Duration of antiviral therapy was recorded for 29 individuals with HBV monoinfection (median 29 months) and 27 individuals with HIV coinfection (median 37 months); p=0.1.

In the HBV/HIV coinfected group, 37/38 adults were on antiviral therapy that included HBV-active agents (TDF and/or 3TC); one patient was not on therapy. HIV VL data were available for 33/37, being undetectable in 21/33 (64%) and <1000 RNA copies/ml in 5/33 (15%). Overall, suppression of HIV viraemia was associated with suppression of HBV viraemia (p=0.02; Fig 2D, Suppl Fig 2B). However, among individuals with undetectable HIV VL, HBV DNA was still detectable in 5/21 (24%). Among these, one was being treated with 3TC as the only HBV-active agent, with HBV DNA VL 1.0 x 10<sup>5</sup> IU/ml. Suppression of HIV viraemia suggests adherence to cART, and the high HBV viral load is therefore consistent with 3TC resistance. The other four were receiving TDF-based combination therapy, making drug resistance a less likely explanation for HBV viraemia (HBV VL 20-5444 IU/ml). Treatment start date was ≥15 months prior to the date of recruitment (recorded in 3/5 cases), making it unlikely that HBV viraemia was detectable because therapy had only recently been instituted.

## Proportion of untreated HBV monoinfected patients who meet treatment criteria

We reviewed the data for 36 HBV monoinfected individuals off therapy to determine the proportion of these who met treatment criteria. Using South African guidelines [16], 6/36 (17%) were treatment eligible (3/36 HBeAg-positive with HBV DNA >20,000 IU/ml plus 5/36 HBeAgnegative with HBV DNA >2,000 IU/ml, of whom 6/8 had ALT >ULN). Based on the European guidelines, 7/36 (19%) individuals would be eligible for therapy (HBV DNA >2,000 IU/ml and ALT >ULN) [15].

### Prevalence of liver disease: laboratory data

We assessed laboratory data and elastography scores as markers for underlying liver disease. There was no significant difference in ALT or AST between monoinfected vs. coinfected individuals (Suppl. Table 3). For BR, the proportion with an elevated value was higher in the monoinfected than in the coinfected group (albeit not reaching statistical significance, p=0.08; Fig 3A), but the absolute values were significantly higher in those with monoinfection (p=0.003; Fig 3C). Thrombocytopaenia can be an indicator of chronic liver disease as a result of a variety of mechanisms, including splenic sequestration and myelosuppression [26]. Strikingly, all the individuals with moderate/severe thrombocytopaenia were in the HBV monoinfected group (Fig 3B,D) suggesting a subgroup of individuals with established liver disease. We calculated fibrosis

scores from laboratory data, finding a higher proportion of the HBV monoinfected group had scores predictive of cirrhosis/fibrosis (for APRI: p=0.02, Fig 4A; for FIB-4: p=0.1, Fig 4B). Despite no difference in median APRI or FIB-4 between monoinfected and coinfected groups, it is striking that 12/14 individuals with elevated fibrosis scores were in the HBV monoinfected group (Fig 4C, 4D).

## Prevalence of liver disease: elastography and clinical data

Only a small proportion of the cohort had elastography data (n=38/112, 34%). Individuals with HBV/HIV coinfection were more likely to be assessed by elastography, undertaken in 30/38 cases (79%) compared to only 8/74 (11%) of individuals with HBV monoinfection (p<0.0001; Table 1; also significant on multivariate analysis). Among 38 individuals with elastography data, there were slightly higher scores in the HBV monoinfected group compared to those with coinfection, although this did not reach statistical significance (median score 6.9 kPa vs 5.6 kPa, respectively; p=0.3; Table 1).

A greater proportion of the HBV monoinfected group had fibroscan scores that would meet criteria for treatment. A threshold of 6 kPa [21], was exceeded in 4/8 (50%) of monoinfected patients vs. 12/30 (40%) of coinfected patients; while the stringent threshold of 9kPa [15] was exceeded in 3/8 (38%) of monoinfected patients vs 4/30 (13%) coinfected patients. However, due to small numbers in each group, neither of these differences reached statistical significance (p=0.7 and p=0.1, respectively).

We reviewed clinical records for complications reported by specialist doctors in 106 cases. Among these, 18/106 (17%) had documented complications of HBV infection, including 17 cases of cirrhosis (16% prevalence) and 3 cases of HCC (3% prevalence); two patients had both cirrhosis and HCC. All HCC cases occurred in the context of HBV monoinfection. The prevalence of hepatic complications was almost twice as high in HBV monoinfection (14/68; 21%) compared to HBV/HIV coinfection (4/38; 11%), although this difference did not reach statistical significance due to small numbers in each group (p=0.3; Table 1).

## Evidence of renal dysfunction

Chronic kidney disease (CKD) can arise in association with HIV infection, and is also a potential side effect of TDF therapy [28]. Therefore, we examined this cohort for the presence of CKD based on calculation of eGFR, available for 99 individuals. CKD stage II or III was present in

31/99 (31%) of the cohort. However, we found no difference in rates of CKD between individuals with HBV monoinfection vs HBV/HIV coinfection (CKD II/III present in 21/63 (33%) vs 10/36 (28%), respectively, p=0.7). There was no evidence of nephrotoxicity among those on TDF; indeed there was a trend towards increased prevalence of CKD among the untreated group vs those on antiviral treatment (CKD II/III present in 18/63 (29%) vs 13/32 (41%) respectively; p=0.2).

### DISCUSSION

# Context and primary conclusions

Developing a detailed understanding of the characteristics of CHB, and the clinical interplay with coendemic HIV, is important to drive forward improvements in care provision, with gains to be made both for individuals populations. Although successful vaccination campaigns are well established, modelling studies predict long timeframes to elimination [29,30], and programmes to enhance diagnosis and treatment will therefore be crucial in the decade ahead.

The traditional paradigm suggests that patients with HBV/HIV coinfection may have worse outcomes than those with HBV monoinfection, and we confirmed a significantly higher prevalence of HBeAg-positive status in those with HIV coinfection. Despite this, our data indicate that the monoinfected group is disadvantaged compared to those with coinfection, evidenced by the significant association between monoinfection and lower rates of access to appropriate clinical surveillance, lower rates of antiviral treatment (even among those who meet treatment criteria), higher HBV viral loads, more established liver disease (hyperbilirubinaemia, thrombocytopaenia and elevated fibrosis scores), and an increased risk of clinical complications. A previous report from the same setting also documents elevated rates of severe fibrosis in HBV monoinfected compared to their HBV/HIV coinfected counterparts [31], although this observation is not consistent as another African study found elevated APRI scores in patients with coinfection [4].

In our cohort, there was no difference in the prevalence of elevated hepatic transaminases (ALT and AST) between monoinfected and coinfected patient groups. It is important to observe that significant evidence of progressive liver disease can be present even in the absence of abnormalities in conventional 'liver function tests'. This highlights a need for clinical surveillance that is broader than any single serum marker.

The worse overall outcomes among the population with HBV monoinfection may stem from the sustained neglect of HBV infection as a clinical and public health problem [18], relatively complex algorithms for HBV treatment stratification, and less consistent and rigorous access to tenofovir monotherapy [32]. HCC can arise independent of liver fibrosis [16], and therefore even among HBV-infected individuals with no objective evidence of inflammatory or fibrotic liver disease, there is a potential for the emergence of malignancy. Our data raise the hypothesis that adults with HBV monoinfection may be coming to clinical care too late, underlining a pressing need for simplified, scalable approaches to HBV diagnosis as well as treatment [33].

## HBV suppression on therapy

Despite the immunological defect associated with HIV infection and the higher prevalence of HBeAg+ status in this group, HBV viraemia can be successfully suppressed in the majority of coinfected patients using conventional TDF-based cART regimens. However, even on appropriate antiviral therapy, over a quarter of patients still had detectable HBV viraemia. This may be explained by sub-optimal adherence to therapy, pharmacokinetics (drug absorption, levels within liver tissue), or drug resistance, and the long timeframes over which HBV viraemia may decline on therapy [34]. Careful clinical surveillance is therefore important even in the context of treatment, while there is a need for further studies to investigate TDF resistance [8].

## Changes to cART regimens with influence on HBV therapy

Changes to cART recommendations are developing, based on the success of dual therapy with dolutegravir (DTG) regimens, both in the context of prior viraemic suppression [35] and for salvage after failure of first-line treatment [36,37]. DTG/3TC is a common combination, but other regimens do not contain any HBV active agents, (e.g. DTG combined with rilpivirine (RPV) [38], emtricitabine (FTC) [39], or ritonavir-boosted lopinavir (LPVr) [37]). These regimens have not yet been robustly evaluated in African populations, and are deemed inappropriate in the context of HBV coinfection [40], although there are data demonstrating the efficacy of TDF/FTC in mediating HBV suppression [41]. As dual therapy combinations enter clinical practice in Africa, enhanced awareness and scrutiny will be critical to ensure that HBV-positive individuals are diagnosed and treated with appropriate HBV-active agents, and that there is caution regarding the potential for selection of HBV drug resistance on DTG/3TC treatment.

## Drug resistance

We identified a patient with phenotypic evidence of 3TC-resistant HBV in our cohort, congruent with evidence for the consistent selection of resistance among individuals on 3TC monotherapy [42], and in keeping with another African study that documented a high prevalence of 3TC resistance among coinfected patients [4]. Tenofovir resistance is less well substantiated, and can be difficult to confirm phenotypically due to the slow rate of HBV DNA suppression after institution of therapy [26]; however, there are reports confirming the potential for resistance to this agent (as previously reviewed [8]).

## Caveats and limitations

We have studied a small cohort, representing a distinct geographical setting and focusing on clinical care delivery within the specific environment of a tertiary care university hospital, which benefits from enhanced resource and infrastructure compared to many other healthcare settings. Even in this setting, missing data are problematic. Assessment with elastography is not consistently deployed, and serological markers are expensive, and not routinely undertaken at each clinic visit. Our small cohort may be underpowered to identify true associations, as reflected by borderline statistical significance of some of the relationships that we observe.

On the one hand, our study may be biased by the likelihood that patients with more advanced pathology are most likely to be diagnosed and referred for tertiary-level follow-up; this could lead to us over-estimating liver disease in those with HBV monoinfection. On the other hand, outside this specific setting, the majority of cases of HBV monoinfection are undiagnosed, and those with a diagnosis are less likely to be under routine surveillance, less likely to be stratified for treatment, and less likely to receive a regular supply of appropriate therapy supported by clinical monitoring; on these grounds, our cohort significantly under-represents the true burden of liver disease. However, irrespective of the magnitude of the effect, head-to-head comparison of comparable monoinfected and coinfected groups within this setting consistently suggest a treatment advantage in the coinfected group, and a risk of continued emergence of liver pathology among those with HBV monoinfection.

We have used platelet count as a marker of liver disease, but this is a non-specific approach, as thrombocytopaenia has diverse potential causes. The sensitivity and specificity of APRI and FIB-4 varies between settings, and further evaluation is specifically required in African populations [43]. We were unable to apply other fibrosis scores, such as gamma-

glutamyltranspeptidase-to-platelet ratio (GPR) [43,44], as the extended panel of liver function tests required is not routinely collected.

We have taken a cross-sectional view, from which long-term outcomes can only be extrapolated with caution. We have not been able to capture data regarding important influences on HBV and HIV viral loads, including compliance with treatment and the presence of antiviral resistance. HBV genotype data are not available for this cohort, but are known to have a role in disease progression, and may add future insights [7,45].

## **Conclusions**

 High standards of provision of HIV services, with consistent access to diagnosis, surveillance and tenofovir-based treatment, are advantageous in delivering a high standard of clinical care for those with HBV coinfection. The majority of HBV monoinfected patients remain undiagnosed, but - even among those who know their status and are under follow-up - there remains a gap in care provision, rendering them susceptible to long-term liver complications. In order to make progress towards 2030 elimination goals, service providers should capitalise on the existing infrastructure and investment deployed for HIV as both a precedent and a foundation for improved clinical care for HBV infection.

 PCM and the OXSAHEP cohort are funded by Wellcome (grant ref 110110).

ACKNOWLEDGEMENTS

We are grateful to the clinic and laboratory staff in infectious diseases, virology and gastroenterology at Tygerberg Hospital, Cape Town, and to the patients for their participation in this study.

CONFLICTS OF INTEREST

Nil to declare

## FIGURE LEGENDS

Figure 1: Summary of cohort of 112 adults with HBV infection from Cape Town, South Africa, showing numbers with HBV monoinfection and HIV/HBV coinfection, those receiving therapy and those with suppressed viraemia. Viral load data were not available in 21 cases, of whom 13 were HBV monoinfected and 8 were HBV/HIV coinfected (shown in dashed lines and box). Green boxes indicate number with suppressed viraemia, yellow indicate number with one virus suppressed and the other detectable, red indicate number with no viraemic suppression.

Figure 2: Characteristics of adults with CHB, based on HBeAg status, HBV therapy and virologic outcomes of therapy, comparing those with HBV monoinfection vs HBV/HIV coinfection from a cross-sectional study in Cape Town, South Africa. A: Proportion of each group testing HBeAg-positive. B: Proportion of monoinfected vs coinfected adults receiving antiviral therapy; C: Proportion of monoinfected vs coinfected adults with HBV suppressed below the limits of detection (<20 IU/ml) on antiviral therapy. D: HBV/HIV co-infected individuals only, showing proportion who have suppressed HIV and/or HBV viral load on antiviral therapy. In all cases, p-values calculated by Fisher's Exact Test, and the number of individuals represented in each group is shown in brackets below the columns.

Figure 3: Assessment of liver disease in adults with HBV monoinfection vs HBV/HIV coinfection in a cross-sectional study in Cape Town, South Africa based on serum bilirubin and platelet count. BR - serum bilirubin; Plt - platelet count. Panels A and B: p-values by Fisher's Exact Test comparing the number in each group falling above and below specified thresholds (BR>17 mmol/L; moderate/severe thrombocytopaenia defined as plt <75 x 10³/μl). Number in each group indicated in brackets under the columns; this varies according to data availability. Panels C and D: p-values by Mann Whitney test; bars indicate median and IQR. C: serum bilirubin levels are significantly elevated in the group with HBV monoinfection. D: Distribution of plt highlights all of those with moderate/severe thrombocytopaenia (below dashed line) are in HBV monoinfected group.

Figure 4: Assessment of liver disease using fibrosis scores derived from laboratory data in adults with HBV monoinfection vs HBV/HIV coinfection in a cross-sectional study of adults in Cape Town, South Africa. APRI - AST to Platelet Ratio Index; FIB-4 - Fibrosis-4 score (for formulae, see methods). Number in each group indicated in brackets under the columns; this varies according to data availability. Panels A and B: p-values by Fisher's Exact Test comparing the number in each group falling above and below the threshold for cirrhosis/fibrosis (APRI >2; FIB-4 >3.25). Panels C and D: p-values by Mann Whitney test and bars indicate median and IQR. No significant difference in median value for either score, but the scatter plots show that individuals with scores above the threshold are predominantly in the mono-infected group.

Table 1: Summary of clinical and laboratory parameters recorded from a cohort of 112 adults with HBV infection in Cape Town, South Africa, comparing groups with HBV monoinfection (n=74) versus HIV/HBV coinfection (n=38). For extended version of table, see Suppl data table 3.

	Whole Cohort	HBV monoinfection	HIV/HBV coinfection	p-value <sup>a</sup>
Sex M:F (% male)	62:50 (55%)	44:30 (59%)	18:20 (47%)	0.24
Median age in years at enrollment <sup>b</sup> (IQR)	44 (36-53)	46 (36-55)	41 (37-50)	0.28
Median body weight in kg <sup>c</sup> (IQR)	73 (60-85)	75 (60-87)	72 (59-80)	0.20
Proportion HBeAg positive <sup>d</sup> (%)	20/102 (19.6%)	8/67 (11.9%)	12/35 (34.3%)	0.009
Proportion with elevated ALT above ULN <sup>e</sup> (%)	49/109 (45%)	33/72 (46%)	16/37 (43%)	0.84
Proportion with elevated AST above ULN <sup>f</sup> (%)	27/85 (32%)	16/50 (32%)	11/35	1.0
Median BR <sup>g</sup> , mmol/L (IQR)	7 (5-13)	9 (5-15)	5 (4-9)	0.003
Proportion with elevated BR above ULN <sup>9</sup> (%)	14/95 (14.7%)	12/61 (19.7%)	2/34 (6.0%)	0.08
Median platelet count <sup>h</sup> , x10 <sup>3</sup> / ul (IQR)	226 (158-292)	227 (153-291)	249 (166-307)	0.38
Proportion with thrombocytopaenia (%)	10/97 (10.3%)	10/62 (16%)	0/35 (0%)	0.01
Proportion with APRI score >2	8/79 (10%)	8/47 (17%)	0/32 (0%)	0.02
Proportion with FIB-4 score >3.25	12/78 (15%)	10/46 (22%)	2/32 (6%)	0.11
Proportion assessed by elastography (%)	38/112 (34%)	8/74 (11%)	30/38 (79%)	<0.0001*
Proportion with elastography score >9kPa (%)	7/38 (18%)	3/8 (38%)	4/30 (13%)	0.14

IQR = inter-quartile range; ALT = alanine transferase; ULN = upper limit of normal. <sup>a</sup>p-value for categorical variables by Fisher's Exact Test, and for continuous variables by Mann Whitney test. <sup>b</sup>Age available for 111/112 individuals. <sup>c</sup>Body weight available for 108/112 individuals. <sup>d</sup>HBeAg status available for 102/112 individuals. <sup>e</sup>ALT available for 60/62 males and 49/50 females, with ULN defined as 19 iu/ml for females and 30 iu/ml for males. <sup>f</sup>AST available for 85/112 individuals, with ULN defined as 40 iu/ml. <sup>g</sup>BR available for 95/112 individuals; ULN defined as 17 mmol/L.

<sup>h</sup>Platelet count available for 97/112 individuals; moderate/severe thrombocytopaenia defined as platelet count <75 x10<sup>3</sup> / ul [26]. <sup>i</sup>CKD (chronic kidney disease) stages II and III defined as eGFR <90 ml/min/1.73m<sup>2</sup>. <sup>i</sup>Clinical complications reviewed for 108/112 individuals, defined as a documented diagnosis of HCC and/or cirrhosis. <sup>k</sup>Elastography data available for 38/112 individuals. \* Also significant by mutivariate analysis.

Table 2: Summary of antiviral therapy treatment and outcomes from a cohort of 112 adults with HBV infection in Cape Town, South Africa, comparing features of those with HBV monoinfection (n=74) versus HIV/HBV coinfection (n=38).

	. ,			
	Whole Cohort	HBV monoinfection	HIV/HBV coinfection	p-value <sup>a</sup>
Proportion on antiviral treatment <sup>b</sup> (%)	71/108 (66%)	34/70 (49%)	37/38 (97)	<0.0001*
Median duration of therapy <sup>c</sup> , months (IQR)	31 (14-66)	29 (7-63)	37 (18-66)	0.1
Median HBV DNA viral load IU/ml <sup>d</sup> (range)	31 (0-1.7x10 <sup>8</sup> )	90 (0 - 1.7x10 <sup>8</sup> )	0 (0-1.0x10 <sup>8</sup> )	0.049
Proportion of HBV viraemia undetectable <sup>e</sup>	40/96 (42%)	20/61 (33%)	20/35 (57%)	0.03

<sup>&</sup>lt;sup>a</sup>p-value for categorical variables by Fisher's Exact Test, and for continuous variables by Mann Whitney test. 
<sup>b</sup>Antiviral treatment data available for 108/112 individuals. <sup>c</sup>Duration of therapy defined for 29 HBV monoinfected and 27 HBV/HIV coinfected individuals. <sup>d</sup>HBV DNA viral load available for 61/74 HBV monoinfected and 35/38 HIV coinfected individuals. <sup>e</sup>Undetectable HBV DNA defined as viral load in serum below limit of detection of assay (typically HBV DNA <20 IU/ml). \* Also significant by mutivariate analysis.

## **SUPPLEMENTARY MATERIAL:**

- **Suppl table 1: STROBE statement** (STrengthening the Reporting of OBservational studies in Epidemiology) to support the quality of this observational cross-sectional study.
- Suppl table 2: Raw data collected for 112 adults with chronic hepatitis B virus infection recruited into a cross-sectional cohort in Cape Town, South Africa. These data are available on-line: https://figshare.com/s/756eff7c317ef041cf0e. This link will be converted to a permanent open access DOI (10.6084/m9.figshare.9649400) on acceptance of the paper for publication.
- Suppl table 3: Summary of parameters recorded from a cohort of 112 adults with HBV infection in Cape Town, South Africa, comparing features of those with HBV monoinfection (n=74) versus HIV/HBV coinfection (n=38). This is an extended version of tables 1 and 2 presented in the main text.
- Suppl Fig 1: Ethnic origins (birth country) of participants enrolled into a cross-sectional cohort of HBV infection in Cape Town, South Africa.
- Suppl Fig 2: Plasma viral loads for HBV and HIV in a cross-sectional study of adults in Cape Town, South Africa. (A) Distribution of HBV DNA viral load in individuals with HBV monoinfection and HBV/HIV coinfection; horizontal lines indicate median with whiskers representing IQR; the numbers shown in brackets under each category report the number of individuals represented; p-values by Mann Whitney U test. (B) Relationship between HIV viral load and HBV viral load in serum, with R<sup>2</sup> and p values by linear regression based on log<sub>10</sub> viral load; note the point where HIV and HBV VL=0 represents 18 individuals.

### REFERENCES

- 1. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV
- coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol.
- 562 2014;61: 20–33.
- 563 2. Griggs D, Stafford-Smith M, Gaffney O, Rockstrom J, Ohman MC, Shyamsundar P, et al.
- Policy: Sustainable development goals for people and planet. Nature. 2013;495: 305–307.
- 565 3. van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B and
- 566 C co-infection among HIV-infected adults while on antiretroviral treatment: long-term
- survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One.
- 568 2014;9: e88552.
- 569 4. Ndow G, Gore ML, Shimakawa Y, Suso P, Jatta A, Tamba S, et al. Hepatitis B testing and
- 570 treatment in HIV patients in The Gambia-Compliance with international guidelines and
- 571 clinical outcomes. PLoS One. 2017;12: e0179025.
- 572 5. Christian B, Fabian E, Macha I, Mpangala S, Thio CL, Ulenga N, et al. Hepatitis B virus
- 573 coinfection is associated with high early mortality in HIV-infected Tanzanians on
- 574 antiretroviral therapy. AIDS. 2019;33: 465–473.
- 575 6. Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence and
- 576 Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South
- 577 Africa and Botswana. PLoS One. 2015;10: e0134037.
- 578 7. McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights
- 579 From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
- 580 Gastroenterology. 2018; doi:10.1053/j.gastro.2018.07.058
- 8. Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti A-M, Goedhals D, et al. A
- 582 systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A
- call for urgent action. PLoS Negl Trop Dis. 2018;12: e0006629.
- 9. Park E-S, Lee AR, Kim DH, Lee J-H, Yoo J-J, Ahn SH, et al. Identification of a quadruple
- mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol.
- 586 2019;70: 1093–1102.

- 10. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et
- 588 al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med.
- 589 2015;373: 795–807.
- 11. 90-90-90: treatment for all [Internet]. [cited 7 Aug 2019]. Available:
- 591 https://www.unaids.org/en/resources/909090
- 12. HIV/AIDS Treatment Guidelines. In: AIDSinfo [Internet]. [cited 7 Aug 2019]. Available:
- 593 https://aidsinfo.nih.gov/guidelines
- 13. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult
- antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18: 776.
- 14. Overview | Hepatitis B (chronic): diagnosis and management | Guidance | NICE. Available:
- 597 http://nice.org.uk/guidance/cg165
- 598 15. European Association for the Study of the Liver. Electronic address:
- easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017
- 600 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol.
- 601 2017;67: 370–398.
- 16. Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C, et
- al. South African guideline for the management of chronic hepatitis B: 2013. S Afr Med J.
- 604 2013;103: 337–349.
- 605 17. Organization WH, Others. Combating hepatitis B and C to reach elimination by 2030:
- advocacy brief [Internet]. World Health Organization; 2016. Available:
- 607 https://apps.who.int/iris/bitstream/handle/10665/206453/WHO HIV 2016.04 eng.pdf
- 18. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B
- virus infection as a neglected tropical disease. PLoS Negl Trop Dis. 2017;11: e0005842.
- 19. Aberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, et al. The WHO
- guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in
- 612 Ethiopia. J Hepatol. 2019;70: 1065–1071.
- 20. Data Management and Workflow Software for Research LabKey. In: LabKey [Internet].
- [cited 22 Aug 2019]. Available: https://www.labkey.com/

- 21. Nice Clinical Guideline, Hepatitis B (chronic): diagnosis and management [Internet]. NICE
- 616 Clinical Guideline; 2013.
- 22. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a
- simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
- 619 [Internet]. Hepatology. 2006. pp. 1317–1325. doi:10.1002/hep.21178
- 620 23. Lin Z-H, Xin Y-N, Dong Q-J, Wang Q, Jiang X-J, Zhan S-H, et al. Performance of the
- aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related
- fibrosis: An updated meta-analysis [Internet]. Hepatology. 2011. pp. 726–736.
- 623 doi:10.1002/hep.24105
- 624 24. Chou R, Wasson N. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic
- Hepatitis C Virus Infection [Internet]. Annals of Internal Medicine. 2013. p. 807.
- 626 doi:10.7326/0003-4819-158-11-201306040-00005
- 627 25. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using
- standardized serum creatinine values in the modification of diet in renal disease study
- equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145: 247–254.
- 630 26. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al.
- Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48: 1000–1007.
- 632 27. Matthews P, Maponga T, Mofokeng M, Goedhals D. Hepatitis B virus (HBV) patient
- 633 information leaflet [Internet]. 2019. doi:10.6084/m9.figshare.8969654.v1
- 634 28. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology.
- 635 2009;49: S185–95.
- 636 29. McNaughton AL, Lourenço J, Hattingh L, Adland E, Daniels S, Van Zyl A, et al. HBV
- vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical
- 638 cohort and dynamic model. BMC Med. 2019;17: 43.
- 30. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for
- global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16: 1399–1408.
- 31. Maponga TG, Andersson MI, van Rensburg CJ, Arends JE, Taljaard J, Preiser W, et al.
- 642 HBV and HIV viral load but not microbial translocation or immune activation are associated

- with liver fibrosis among patients in South Africa. BMC Infect Dis. 2018;18: 214.
- 32. Maponga TG, Nwankwo C, Matthews PC. Sustainable Development Goals for HBV
- 645 elimination in South Africa: challenges, progress, and the road ahead. South African
- 646 Gastroenterology Review. 2019;17: 15–25.
- 33. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al.
- Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology
- 649 Commission. Lancet Gastroenterol Hepatol. 2019;4: 135–184.
- 34. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of
- 651 HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
- 652 PLoS One. 2013;8: e68152.
- 35. Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy
- with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-
- term data from clinical practice. J Antimicrob Chemother. 2019; doi:10.1093/jac/dkz009
- 36. Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, et al.
- Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage
- regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials.
- 659 2018;19: 242–248.
- 37. Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir
- 661 versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor
- therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an
- open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19: 253–264.
- 38. Casado JL, Monsalvo M, Fontecha M, Vizcarra P, Rodriguez MA, Vivancos MJ, et al.
- Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected
- patients in a clinical setting. HIV Res Clin Pract. 2019;20: 64–72.
- 39. Diaco ND, Strickler C, Giezendanner S, Wirz SA, Tarr PE. Systematic De-escalation of
- 668 Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus
- 669 Emtricitabine or Lamivudine in Swiss HIV-positive Persons. EClinicalMedicine. 2018;6: 21–
- 670 25.
- 40. Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19: 713–738. 41. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013;56: e87-94. 42. Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, et al. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. PLoS One. 2015;10: e0134539. 43. O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, et al. Liver function tests and fibrosis scores in a rural population in Africa: estimation of the burden of disease and associated risk factors [Internet]. Gastroenterology. medRxiv; 2019. doi:10.1101/19000968 44. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gammaglutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65: 1369–1376. 45. Kramvis A. Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus. S Afr Med J. 2018;108: 17–21.







